- Trial Phase
- Approved (FDA-approved biosimilar referencing Lucentis; US commercial launch July 2026)
- Time to Market
- Already on the market — Harrow announced the US commercial launch of BYOOVIZ on July 1, 2026.
- Why 3/10
- BYOOVIZ is already FDA-approved and was commercially launched in the US on July 1, 2026, with no pending PDUFA or pivotal readout for this drug in the next ~12 months — the only near-term drivers are quarterly sales-ramp metrics (not a binary), so per the rubric an approved, commercializing product with no pending regulatory decision scores 3.
Watch Harrow's quarterly disclosures for BYOOVIZ launch-quarter revenue and unit data (first full quarter lands with Q3 2026 earnings) — the launch is a growth add-on, not the company's only story (VEVYE, IHEEZO, TYRVAYA). Note the stock carries high short positioning: FINRA semi-monthly data show ~6.78M shares short as of the 7/31/2026 settlement (~18.2% of estimated shares outstanding, ~11.8 days to cover), so positive/negative launch headlines can move the shares sharply; analyst consensus is strong-buy with a mean price target of $67.50 (~48% above the $41.64 close).
Price Chart
Executive Summary
BYOOVIZ (ranibizumab-nuna) is an FDA-approved, interchangeable biosimilar of Lucentis that Harrow, Inc. (Nasdaq: HROW), a Nashville-based ophthalmic company, began selling in the US on July 1, 2026 as the anchor of its growing retina portfolio. It is already commercialized — the defining regulatory binary has passed — so the investment question is execution: how fast BYOOVIZ (plus VEVYE, IHEEZO, and the pending TYRVAYA acquisition) can drive Harrow's reiterated $350M-$365M 2026 revenue guidance, which implies a steep second-half ramp. Company-level signals are mixed: analysts rate the stock strong-buy (mean PT $67.50 vs. $41.64 close), and several funds added Q2 2026 13F positions, but FINRA data show ~18.2% of estimated shares outstanding short and heavy daily short-volume flow, while Q2 2026 swung to a $17.3M GAAP net loss on heavy sales-force/R&D investment.
How It Works
BYOOVIZ is a biosimilar (a near-copy of an already-approved biologic) of ranibizumab, the drug sold by Roche/Genentech as Lucentis. It is a small antibody fragment injected directly into the eye that blocks VEGF-A, a protein that drives abnormal blood-vessel growth and fluid leakage in the retina. It is used to treat retinal diseases such as wet age-related macular degeneration and diabetic macular edema. Harrow markets BYOOVIZ as an "interchangeable" ranibizumab biosimilar — meaning, in effect, it can be substituted for Lucentis at the pharmacy level without a new prescription.
Trial Status
No pivotal trials — BYOOVIZ is an already-approved biosimilar. Harrow is in the commercial launch phase: on July 20, 2026 it presented three studies at ASRS 2026 supporting BYOOVIZ (including a large real-world safety analysis); the July 1, 2026 launch PR and the August 10, 2026 Q2 earnings release both cite BYOOVIZ as a new pipeline/commercial catalyst.
The Two-Sided Case
Upcoming Catalysts
- Q3 2026 earnings (~Nov 2026): first full quarter of BYOOVIZ launch revenue and any management commentary on retina market share.
- Quarterly prescription/unit data for the retina portfolio (BYOOVIZ, IHEEZO).
- Company-level, not BYOOVIZ-specific: TYRVAYA acquisition expected to close H2 2026; QUELL trial topline data expected Q4 2026 — both can move HROW regardless of BYOOVIZ.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Harrow, Inc. Press Release HROW ·Originating report